Researchers say that inhibiting NLRP3 with Dapansutrile could be an effective strategy to prevent melanoma tumour growth.
List view / Grid view
A combination of checkpoint and small molecule inhibitors showed success at targeting Myc oncogenes in mouse neuroblastoma and melanoma models.
Vito Quaranta, professor of biochemistry and pharmacology, discusses how cancerous cells adopting novel mechanisms of energy production could be sensitised to existing therapies with a focus on melanoma.
Researchers have discovered that in mice with cancers in the liver, immunotherapy and radiotherapy prevented T-cell death.
Immunology study shows that NF-kappa B-inducing kinase (NIK) is critical to T cell metabolism and the antitumour immune response.
The Junior Editors of Drug Target Review, Victoria Rees and Hannah Balfour, discuss some of the most noteworthy news and announcements from this year.
Scientists have shown that age may cause genetically identical melanoma skin cancer cells to respond differently to treatment, making age a primary factor in treatment response.
Researchers have implicated long non-coding RNAs in tumour progression and suggest they may be potential drug targets for cancers with p53 mutations.
Researchers demonstrate that their novel small molecule, which activates the STING protein, supresses tumour growth and metastasis in a murine model of aggressive melanoma.
A new study conducted in Israel suggests that T cells’ ability to destroy skin cancer increases in the absence of T-cell regulators called SLAMF6.
Researchers have revealed that the WDR74 protein plays a key role in lung cancer and melanoma, including metastasis, indicating it may be a potential drug target.
An innovative new vaccine technique, which sensitises the immune system to the genetic signature of APOBEC mutations (often found in cancers), increases the efficacy of immunotherapies.
A study of published papers has revealed the importance of research into how the microbiome affects the development of melanoma.
A study has shown that long non-coding RNA called DIRC3 can block melanoma growth and could be used to identify new targets for skin cancer therapies.
Upregulation of the c-Cbl gene causes degradation of the immune checkpoint protein PD-1 and may provide a possible new avenue for cancer therapies, according to researchers.